Steroidogenic Cytochrome P450 17A1 Structure and Function

Overview

Journal Mol Cell Endocrinol

Specialties Cell Biology
Endocrinology
Molecular Biology

Date 2021 Mar 30

PMID 33781841

Citations 19

Authors

Sarah D Burris-Hiday

Emily E Scott

Affiliations

Soon will be listed here.

Abstract

Cytochrome P450 17A1 (CYP17A1) is a critical steroidogenic enzyme, essential for producing glucocorticoids and sex hormones. This review discusses the complex activity of CYP17A1, looking at its role in both the classical and backdoor steroidogenic pathways and the complex chemistry it carries out to perform both a hydroxylation reaction and a carbon-carbon cleavage, or lyase reaction. Functional and structural investigations have informed our knowledge of these two reactions. This review focuses on a few specific aspects of this discussion: the identities of reaction intermediates, the coordination of hydroxylation and lyase reactions, the effects of cytochrome b, and conformational selection. These discussions improve understanding of CYP17A1 in a physiological setting, where CYP17A1 is implicated in a variety of steroidogenic diseases. This information can be used to improve ways in which CYP17A1 can be effectively modulated to treat diseases such as prostate and breast cancer, Cushing's syndrome, and glioblastoma.

Citing Articles

Selective -Hydroxyketone Formation and Subsequent C-C Bond Cleavage by Cytochrome P450 Monooxygenase Enzymes.

Lee J, Coleman T, McLean M, Podgorski M, Hayball E, Stone I ACS Catal. 2025; 14(11):8958-8971.

PMID: 39911918 PMC: 11793330. DOI: 10.1021/acscatal.4c01766.

Abiraterone and Galeterone, Powerful Tools Against Prostate Cancer: Present and Perspective.

Kuzminac I, Nikolic A, Savic M, Ajdukovic J Pharmaceutics. 2024; 16(11).

PMID: 39598525 PMC: 11597628. DOI: 10.3390/pharmaceutics16111401.

Computational Investigation of the Therapeutic Potential of in the Management of Erectile Dysfunction.

Ejeje J, Agbebi E, Mathenjwa-Goqo M, Oje O, Agboinghale P, Ebe I Int J Mol Sci. 2024; 25(22).

PMID: 39596427 PMC: 11594949. DOI: 10.3390/ijms252212362.

Unraveling the complexity of follicular fluid: insights into its composition, function, and clinical implications.

Pan Y, Pan C, Zhang C J Ovarian Res. 2024; 17(1):237.

PMID: 39593094 PMC: 11590415. DOI: 10.1186/s13048-024-01551-9.

Adolescent exposure to a mixture of per- and polyfluoroalkyl substances (PFAS) depletes the ovarian reserve, increases ovarian fibrosis, and alters the Hippo pathway in adult female mice.

Clark K, George J, Davis J Toxicol Sci. 2024; 202(1):36-49.

PMID: 39141488 PMC: 11514835. DOI: 10.1093/toxsci/kfae103.

References

Khatri Y, Gregory M, Grinkova Y, Denisov I, Sligar S . Active site proton delivery and the lyase activity of human CYP17A1. Biochem Biophys Res Commun. 2013; 443(1):179-84. PMC: 3912944. DOI: 10.1016/j.bbrc.2013.11.094. View

Valassi E, Aulinas A, Glad C, Johannsson G, Ragnarsson O, Webb S . A polymorphism in the CYP17A1 gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome. Clin Endocrinol (Oxf). 2017; 87(5):433-439. DOI: 10.1111/cen.13414. View

Nakajin S, Hall P . Microsomal cytochrome P-450 from neonatal pig testis. Purification and properties of A C21 steroid side-chain cleavage system (17 alpha-hydroxylase-C17,20 lyase). J Biol Chem. 1981; 256(8):3871-6. View

Miller W, Auchus R . The "backdoor pathway" of androgen synthesis in human male sexual development. PLoS Biol. 2019; 17(4):e3000198. PMC: 6464227. DOI: 10.1371/journal.pbio.3000198. View

Yamaoka M, Hara T, Hitaka T, Kaku T, Takeuchi T, Takahashi J . Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J Steroid Biochem Mol Biol. 2012; 129(3-5):115-28. DOI: 10.1016/j.jsbmb.2012.01.001. View

Suzuki T, Sasano H, Takeyama J, Kaneko C, Freije W, Carr B . Developmental changes in steroidogenic enzymes in human postnatal adrenal cortex: immunohistochemical studies. Clin Endocrinol (Oxf). 2001; 53(6):739-47. DOI: 10.1046/j.1365-2265.2000.01144.x. View

Guengerich F . Oxidation-reduction properties of rat liver cytochromes P-450 and NADPH-cytochrome p-450 reductase related to catalysis in reconstituted systems. Biochemistry. 1983; 22(12):2811-20. DOI: 10.1021/bi00281a007. View

Brooke G, Bevan C . The role of androgen receptor mutations in prostate cancer progression. Curr Genomics. 2009; 10(1):18-25. PMC: 2699836. DOI: 10.2174/138920209787581307. View

Renfree M, Wilson J, Short R, Shaw G, George F . Steroid hormone content of the gonads of the tammar wallaby during sexual differentiation. Biol Reprod. 1992; 47(4):644-7. DOI: 10.1095/biolreprod47.4.644. View

10.

Kuenen-Boumeester V, van der Kwast T, Claassen C, Look M, Liem G, Klijn J . The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer. 1996; 32A(9):1560-5. DOI: 10.1016/0959-8049(96)00112-8. View

11.

Rampurwala M, Wisinski K, Burkard M, Ehsani S, ORegan R, Carmichael L . Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer. Invest New Drugs. 2016; 35(1):87-94. PMC: 5590750. DOI: 10.1007/s10637-016-0403-2. View

12.

Estrada D, Skinner A, Laurence J, Scott E . Human cytochrome P450 17A1 conformational selection: modulation by ligand and cytochrome b5. J Biol Chem. 2014; 289(20):14310-20. PMC: 4022897. DOI: 10.1074/jbc.M114.560144. View

13.

Gao Q, Doneanu C, Shaffer S, Adman E, Goodlett D, Nelson S . Identification of the interactions between cytochrome P450 2E1 and cytochrome b5 by mass spectrometry and site-directed mutagenesis. J Biol Chem. 2006; 281(29):20404-17. DOI: 10.1074/jbc.M601785200. View

14.

Daff S, Chapman S, Turner K, Holt R, Govindaraj S, Poulos T . Redox control of the catalytic cycle of flavocytochrome P-450 BM3. Biochemistry. 1997; 36(45):13816-23. DOI: 10.1021/bi971085s. View

15.

Gonzalez E, Johnson K, Pallan P, Phan T, Zhang W, Lei L . Inherent steroid 17α,20-lyase activity in defunct cytochrome P450 17A enzymes. J Biol Chem. 2017; 293(2):541-556. PMC: 5767860. DOI: 10.1074/jbc.RA117.000504. View

16.

DeVore N, Scott E . Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. Nature. 2012; 482(7383):116-9. PMC: 3271139. DOI: 10.1038/nature10743. View

17.

Morgan E, Coon M . Effects of cytochrome b5 on cytochrome P-450-catalyzed reactions. Studies with manganese-substituted cytochrome b5. Drug Metab Dispos. 1984; 12(3):358-64. View

18.

Fehl C, Vogt C, Yadav R, Li K, Scott E, Aube J . Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2. J Med Chem. 2018; 61(11):4946-4960. PMC: 6367708. DOI: 10.1021/acs.jmedchem.8b00419. View

19.

Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R . Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based.... J Clin Oncol. 2015; 33(7):723-31. PMC: 4879718. DOI: 10.1200/JCO.2014.56.5119. View

20.

Akhtar M, Wright J, Lee-Robichaud P . A review of mechanistic studies on aromatase (CYP19) and 17α-hydroxylase-17,20-lyase (CYP17). J Steroid Biochem Mol Biol. 2010; 125(1-2):2-12. DOI: 10.1016/j.jsbmb.2010.11.003. View